98% of healthcare executives believe automated healthcare will improve gaps in care

In a report released by World Business Research (WBR) and Conversa Health, 98 percent of healthcare executives believed automated healthcare will be important to closing gaps in transactional care, continuous and collaborative care experiences.

The report, titled “Healthcare 2020: How Automated Patient Experiences Will Transform the Landscape,” included responses collected from interviews and surveys of134 healthcare executives. The report aimed to provide insight into how executives view automated healthcare technology, how their organization would utilize these tools and future plans of adoption.

Key findings included:

  • 87 percent of respondents believed automated healthcare would be beneficial to increasing patient engagement in their own care.
  • 82 percent of respondents see value in using automated healthcare solutions to gather patient-generated health data (PGHD).
  • 79 percent of respondents plan on integrating automated healthcare solutions within the next 24 months.
  • 49 percent of respondents are either integrating or already have integrated PGHD into their patient experience initiatives.
  • 74 percent of respondent are interested in the use of automated healthcare / AI solutions for improving continuous care experiences for their patients.
  • 98 percent of respondents think automated healthcare will help close gaps in current standards of care.

“We have been using automated technology and it has exceeded my expectations,” said Margaret Sabin, the CEO of Penrose- St. Francis Health Services, of Centura Health. “It has enabled us to engage with our patients in a way that’s convenient for them, and gives us the kind of information we need to help them manage their lives.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.